Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers
Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers
复制标题
DOI：
10.1016/j.jhep.2011.12.025
复制
发表时间：
2012-06-01
影响因子：
25.7
通讯作者：
Wong, Vincent Wai-Sun
中科院分区：
文献类型：
--
作者：
Shen, Jiayun;Chan, Henry Lik-Yuen;Wong, Vincent Wai-Sun
背景与目的：非酒精性脂肪性肝病(NAFLD)和脂肪性肝炎(NASH)的诊断受到肝脏活检的限制。目的：探讨细胞角蛋白-18片段(CK-18)、脂肪细胞脂肪酸结合蛋白(AFABP)和成纤维细胞生长因子21(FGF21)对NAFLD和NASH诊断的准确性。结果：正常对照组(中位数103U/L，15.4 ng/ml，104pg/ml)、非NASH组(263U/L，18.9 ng/ml，249pg/ml)和NASH组(418U/L，19.4 ng/ml，354pg/ml)血清CK-18，AFABP，FGF21水平依次升高(P<0.05)。
Background & Aims: The diagnosis of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) is limited by the need for liver biopsy. We aimed at testing the accuracy of cytokeratin-18 fragment (CK-18), adipocyte fatty acid binding protein (AFABP) and fibroblast growth factor 21 (FGF21) for the diagnosis of NAFLD and NASH.Methods: 146 patients with biopsy-proven NAFLD and 74 age- and gender-matched healthy controls were included. Serum CK-18, AFABP and FGF21 levels were determined by enzyme-linked imnnunosorbent assay.Results: Serum CK-18, AFABP, and FGF21 increased in a stepwise fashion in control subjects (median 103 U/L, 15.4 ng/ml, and 104 pg/ml), patients with non-NASH NAFLD (263 U/L, 18.9 ng/ml, and 249 pg/ml) and NASH (418 U/L, 19.4 ng/ml, and 354 pg/ml) (p